RÉSUMÉ
AIM: To investigate whether children with perinatal brain injury have impairments in specific components of visual attention, and whether early dietary supplementation can reduce any deficits. METHOD: Children participating in the Dolphin neonatal trial of dietary supplementation were tested at age 6 months with the Infant Fixation Shift Attention Test, and at 4 to 5 years with four subtests of the Early Childhood Attention Battery (ECAB) assessing different components of attention (selective, sustained, and executive function), and the Fluid Crystallized Intelligence Index of the Kaufman Assessment Battery for Children, Second Edition (KABC-II). From 59 children originally assigned to trial groups, 33 were available for testing at 4 to 5 years (18 treatment group of whom seven, six, and five showed mild, moderate, or severe neonatal brain injury; 15 controls with one, seven, and seven in the neonatal brain injury categories respectively). Given the imbalance in numbers with mild brain injury, analysis of trial group differences is restricted to moderate and severe brain injury severities (n=25). RESULTS: Children with perinatal brain injury showed poorer attention across all components relative to age norms (mean standard scores 75-87; p<0.001 for three of the four subtests), with the greatest impairment in sustained attention. These impairments remained when compared with cognitive age assessed using the Fluid Crystallized Intelligence Index. Impairment was reduced in the treatment compared to the control group (p=0.04 for flanker test, p=0.002 for counterpointing, and p=0.027 for the overall ECAB score). INTERPRETATION: Perinatal brain injury is associated with later impaired attention, beyond that predicted from any general cognitive disability. Impairment varies across attention components, being most severe for sustained attention. The effects on flanker and counterpointing suggest that dietary supplementation from 0 to 2 years of age may reduce attention problems. Measuring the different components of attention is important when considering assessment and interventions for children with perinatal brain injury.
Sujet(s)
Attention/physiologie , Lésions encéphaliques , Dysfonctionnement cognitif , Compléments alimentaires , Fonction exécutive/physiologie , Maladies néonatales , Intelligence/physiologie , Lésions encéphaliques/complications , Lésions encéphaliques/physiopathologie , Enfant d'âge préscolaire , Dysfonctionnement cognitif/diétothérapie , Dysfonctionnement cognitif/étiologie , Dysfonctionnement cognitif/physiopathologie , Femelle , Humains , Nourrisson , Nouveau-né , Maladies néonatales/physiopathologie , Études longitudinales , Mâle , Acuité des besoins du patient , Résultat thérapeutiqueRÉSUMÉ
Invasive fungal infections remain the leading causes of morbidity and mortality in neonates, especially preterm and very low birth weight infants. Most invasive fungal infections are due to Candida or Aspergillus species, and other fungi are increasingly reported and described. Appropriate identification and treatment are required to augment activity and reduce the toxicity of antifungal drugs. Successful use of antifungals in the vulnerable neonatal population is important for both prevention and treatment of infection. Strategies for prevention, including prophylactic antifungal therapy as well as reducing exposure to modifiable risk factors, like limiting antibiotic exposure, discontinuation of central catheters, and hand hygiene are key techniques to prevent and decrease rates of invasive fungal infections. In conclusion, this is a review of the most common causes, prevention strategies, prophylaxis, and treatment of invasive fungal infections in neonates.
Sujet(s)
Antifongiques/usage thérapeutique , Maladies néonatales/traitement médicamenteux , Infections fongiques invasives/traitement médicamenteux , Humains , Sujet immunodéprimé , Nouveau-né , Maladies néonatales/diagnostic , Maladies néonatales/microbiologie , Maladies néonatales/physiopathologie , Infections fongiques invasives/diagnostic , Infections fongiques invasives/microbiologie , Infections fongiques invasives/physiopathologie , Facteurs de risqueRÉSUMÉ
Perinatal inflammation triggers breathing disturbances early in life and affects the respiratory adaptations to challenging conditions, including the generation of amplitude long-term facilitation (LTF) by acute intermittent hypoxia (AIH). Some of these effects can be avoided by anti-inflammatory treatments like minocycline. Since little is known about the effects of perinatal inflammation on the inspiratory rhythm generator, located in the preBötzinger complex (preBötC), we tested the impact of acute lipopolysaccharide (LPS) systemic administration (sLPS), as well as gestational LPS (gLPS) and gestational chronic IH (gCIH), on respiratory rhythm generation and its long-term response to AIH in a brainstem slice preparation from neonatal mice. We also evaluated whether acute minocycline administration could influence these effects. We found that perinatal inflammation induced by sLPS or gLPS, as well as gCIH, modulate the frequency, signal-to-noise ratio and/or amplitude (and their regularity) of the respiratory rhythm recorded from the preBötC in the brainstem slice. Moreover, all these perinatal conditions inhibited frequency LTF and amplitude long-term depression (LTD); gCIH even induced frequency LTD of the respiratory rhythm after AIH. Some of these alterations were not observed in slices pre-treated in vitro with minocycline, when compared with slices obtained from naïve pups, suggesting that ongoing inflammatory conditions affect respiratory rhythm generation and its plasticity. Thus, it is likely that alterations in the inspiratory rhythm generator and its adaptive responses could contribute to the respiratory disturbances observed in neonates that suffered from perinatal inflammatory challenges.
Sujet(s)
Anti-inflammatoires/pharmacologie , Générateurs centraux de rythme/physiopathologie , Hypoxie/physiopathologie , Maladies néonatales/physiopathologie , Inflammation/traitement médicamenteux , Inflammation/physiopathologie , Minocycline/pharmacologie , Plasticité neuronale/physiologie , Centre respiratoire/physiopathologie , Fréquence respiratoire/physiologie , Animaux , Animaux nouveau-nés , Anti-inflammatoires/administration et posologie , Modèles animaux de maladie humaine , Humains , Nouveau-né , Maladies néonatales/traitement médicamenteux , Inflammation/induit chimiquement , Minocycline/administration et posologieRÉSUMÉ
Bronchopulmonary dysplasia (BPD) is a debilitating disease in premature infants resulting from lung injury that disrupts alveolar and pulmonary vascular development. Despite the use of lung-protective ventilation and targeted oxygen therapy, BPD rates have not significantly changed over the last decade. Recent evidence suggests that sepsis and conditions initiating the systemic inflammatory response syndrome in preterm infants are key risk factors for BPD. However, the mechanisms by which sepsis-associated systemic inflammation and microbial dissemination program aberrant lung development are not fully understood. Progress has been made within the last 5 years with the inception of animal models allowing mechanistic investigations into neonatal acute lung injury and alveolar remodeling attributable to endotoxemia and necrotizing enterocolitis. These recent studies begin to unravel the pathophysiology of early endothelial immune activation via pattern recognition receptors such as Toll-like receptor 4 and disruption of critical lung developmental processes such as angiogenesis, extracellular matrix deposition, and ultimately alveologenesis. Here we review scientific evidence from preclinical models of neonatal sepsis-induced lung injury to new data emerging from clinical literature.
Sujet(s)
Dysplasie bronchopulmonaire/étiologie , Maladies néonatales/physiopathologie , Maladies du prématuré/physiopathologie , Sepsie/complications , Syndrome de réponse inflammatoire généralisée/complications , Dysplasie bronchopulmonaire/anatomopathologie , Humains , Nouveau-né , PrématuréRÉSUMÉ
Infants born with neonatal opioid withdrawal syndrome (NOWS) can display abnormal cardiorespiratory patterns including tachypnea, tachycardia, and impaired ventilatory responses to hypoxia (HVR) and hypercapnia (HCVR). Chronic morphine exposure is associated with increased midbrain microglial expression. Using a rat model of pre- and post-natal morphine exposure, we assessed cardiorespiratory features of NOWS (resting tachycardia and tachypnea) including the attenuated HVR and HCVR and whether they are associated with increased brainstem microglia expression. Pregnant rats (dams) received twice-daily subcutaneous injections of morphine (5 mg/kg) during the third (last) week of pregnancy to simulate 3rd trimester in utero opioid exposure. Offspring then received once-daily subcutaneous injections of morphine (0.5 mg/kg) until postnatal (P) day P10 days of age to simulate postnatal morphine therapy. Cardiorespiratory responses were assessed 24 h later (P11 days) following spontaneous withdrawal. Compared to saline-treated pups, morphine-exposed offspring exhibited tachycardia and tachypnea as well as an attenuated HVR and HCVR. Microglial cell counts were increased in the nucleus tractus solitarius (nTS), dorsal motor nucleus of the vagus (DMNV) and nucleus ambiguous (NAamb), but not the retrapezoid nucleus (RTN) or the non-cardiorespriatory region, the cuneate nucleus (CN). These data suggest that the cardiorespiratory features and autonomic dysregulation in NOWS infants may be associated with altered microglial function in specific brainstem cardiorespiratory control regions.
Sujet(s)
Tronc cérébral , Maladies néonatales , Microglie , Troubles liés aux opiacés , Syndrome de sevrage , Tachycardie , Tachypnée , Animaux , Animaux nouveau-nés , Tronc cérébral/immunologie , Tronc cérébral/physiopathologie , Modèles animaux de maladie humaine , Femelle , Humains , Hypercapnie/immunologie , Hypercapnie/physiopathologie , Hypoxie/immunologie , Hypoxie/physiopathologie , Nouveau-né , Maladies néonatales/étiologie , Maladies néonatales/immunologie , Maladies néonatales/physiopathologie , Microglie/immunologie , Troubles liés aux opiacés/complications , Troubles liés aux opiacés/immunologie , Troubles liés aux opiacés/physiopathologie , Grossesse , Effets différés de l'exposition prénatale à des facteurs de risque/immunologie , Effets différés de l'exposition prénatale à des facteurs de risque/physiopathologie , Rats , Syndrome de sevrage/complications , Syndrome de sevrage/immunologie , Syndrome de sevrage/physiopathologie , Tachycardie/étiologie , Tachycardie/immunologie , Tachycardie/physiopathologie , Tachypnée/étiologie , Tachypnée/immunologie , Tachypnée/physiopathologieRÉSUMÉ
OBJECTIVE: The present study seeks to assess the impact of gestational hypertensive disorders on premature newborns below 34 weeks and to establish the main morbidities and mortality in the neonatal period and at 18 months. MATERIALS AND METHODS: A retrospective observational study was carried out with 695 premature newborns of gestational age (GA) between 24 and 33 weeks and 6 days, born alive in the Neonatal ICU of Brasília's Mother and Child Hospital (HMIB), in the period from January 1, 2014, to July 31, 2019. In total, 308 infants were born to hypertensive mothers (G1) and 387 to normotensive mothers (G2). Twin pregnancies and diabetic patients with severe malformations were excluded. Outcomes during hospitalization and outcomes of interest were evaluated: respiratory distress syndrome (RDS), brain ultrasonography, diagnosis of bronchopulmonary dysplasia (BPD), diagnosis of necrotizing enterocolitis, retinopathy of prematurity, breastfeeding rate at discharge, survival at discharge and at 18 months of chronological age and relationship between weight and gestational age. RESULTS: Newborns with hypertensive mothers had significantly lower measurements of birth weight and head circumference. The G1 group had a higher risk small for gestational age (OR 2.4; CI 95% 1.6-3.6; p <0.00), as well as a greater risk of being born with a weight less than 850 g (OR 2.4; 95% CI 1.2-3.5; p <0.00). Newborns of mothers with hypertension presented more necrotizing enterocolitis (OR 2.0; CI 95% 1.1-3.7); however, resuscitation in the delivery room and the need to use surfactant did not differ between groups, nor did the length of stay on mechanical ventilation, or dependence on oxygen at 36 weeks of gestational age. Survival was better in newborns of normotensive mothers, and this was a protective factor against death (OR 0.7; 95% CI 0.5-0.9; p <0.01). In the follow-up clinic, survival at 18 months of chronological age was similar between groups, with rates of 95.3% and 92.1% among hypertensive and normotensive mothers, respectively. Exclusive breastfeeding at discharge was 73.4% in the group of hypertensive women and 77.3% in the group of normotensive mothers. There were no significant differences between groups. CONCLUSION: Among the analyzed outcomes, arterial hypertension during pregnancy can increase the risk of low weight, small babies for gestational age (SGA), deaths in the neonatal period and enterocolitis, with no differences in weight and survival at 18 months of chronological age. Arterial hypertension presents a high risk of prematurity in the neonatal period, with no difference at 18 months of age.
Sujet(s)
Hypertension artérielle gravidique/épidémiologie , Maladies néonatales/épidémiologie , Complications cardiovasculaires de la grossesse/épidémiologie , Dysplasie bronchopulmonaire , Entérocolite nécrosante/épidémiologie , Entérocolite nécrosante/physiopathologie , Femelle , Âge gestationnel , Humains , Hypertension artérielle gravidique/physiopathologie , Nourrisson , Mortalité infantile , Très grand prématuré/physiologie , Nouveau-né , Maladies néonatales/physiopathologie , Maladies du prématuré/épidémiologie , Maladies du prématuré/physiopathologie , Nourrisson petit pour son âge gestationnel/physiologie , Nourrisson très faible poids naissance/physiologie , Unités de soins intensifs néonatals , Grossesse , Complications cardiovasculaires de la grossesse/physiopathologie , Ventilation artificielle , Syndrome de détresse respiratoire du nouveau-né/épidémiologie , Syndrome de détresse respiratoire du nouveau-né/physiopathologie , Études rétrospectivesRÉSUMÉ
BACKGROUND: Mild hypoxic-ischemic encephalopathy (HIE) constitutes a large unstudied population with considerable debate on how to define and treat due to the dynamic evolution of the clinical signs of encephalopathy. We propose to address this gap with quantitative physiological biomarkers to aid in stratification of the disease severity. The objectives of this prospective cohort study were to measure the electroencephalographic (EEG) power as an objective biomarker of the evolution of the clinical encephalopathy in newborns with mild to severe HIE. METHODS: EEG was collected in infants with HIE using four bipolar electrodes analyzed for the first three hours of the recording. Delta power (DP, 0.5 to 4 Hz) and total power (TP, 0.5 to 20 Hz) were compared between groups with different HIE severity using a univariate ordinal logistic regression model and receiver operating characteristic curves. RESULTS: A total of 44 term-born infants with mild to severe HIE were identified within six hours of birth. The DP and TP values were significantly higher for the mild group than for the moderate group for all bipolar electrodes. A one-unit increase in DP was associated with significantly lower odds of encephalopathy. DP best distinguished mild from higher encephalopathy grades by area under the curve. CONCLUSIONS: We conclude that DP and TP are sensitive real-time biomarkers for monitoring the dynamic evolution of the encephalopathy severity in the first day of life. The quantitative EEG power may lead to timely recognition of the worsening of the encephalopathy and guide future therapeutic interventions targeting mild HIE.
Sujet(s)
Électroencéphalographie , Hypoxie-ischémie du cerveau/diagnostic , Maladies néonatales/diagnostic , Marqueurs biologiques , Ondes du cerveau/physiologie , Femelle , Humains , Hypoxie-ischémie du cerveau/physiopathologie , Nouveau-né , Maladies néonatales/physiopathologie , Mâle , Études prospectivesRÉSUMÉ
INTRODUCTION: Microribonucleic acids (miRNAs) have short (approximately 18 to 25) nucleotides and are evolutionarily conserved and endogenously expressed RNAs belonging to a family of noncoding RNA molecules. miRNA-373 regulates cell proliferation, migration, apoptosis, invasion, and repairing damaged DNA after hypoxia stress. Neonatal hypoxic-ischemic encephalopathy (HIE) refers to perinatal asphyxia caused by partial or complete hypoxia, reduced or suspended cerebral blood flow, and fetal or neonatal brain damage. We aim to investigate the relationship between miRNA-373 and HIF-1α, between miRNA-373 MMP-9, and between miRNA-373 VEGF in the occurrence and development of HIE. METHODS: Human (children) samples were divided into four groups (n = 15 in each group) according to HIE severity. The patient group was divided into middle, moderate, and severe HIE groups. The control group included healthy children or children with nonneurological diseases. The expressions of miRNA-373, HIF-1α, MMP-9, and VEGF were assayed in the serum samples. RESULTS: Our study showed a strong relationship between miRNA-373 and HIF-1α, between miRNA-373 and MMP-9, and between miRNA-373 and VEGF. The expression levels of miRNA-373, HIF-1α, MMP-9, and VEGF in the HIE groups were much higher than those of the control group. CONCLUSION: The increased change in miRNA-373 expression has a certain diagnostic significance on neonatal HIE. In the occurrence and development of HIE, miRNA-373 is positively correlated with HIF-1α, MMP-9, and VEGF.
Sujet(s)
Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Hypoxie-ischémie du cerveau , Maladies néonatales , Matrix metalloproteinase 9/métabolisme , microARN/métabolisme , Biologie informatique , Humains , Sous-unité alpha du facteur-1 induit par l'hypoxie/sang , Sous-unité alpha du facteur-1 induit par l'hypoxie/génétique , Hypoxie-ischémie du cerveau/génétique , Hypoxie-ischémie du cerveau/métabolisme , Hypoxie-ischémie du cerveau/physiopathologie , Nouveau-né , Maladies néonatales/génétique , Maladies néonatales/métabolisme , Maladies néonatales/physiopathologie , Matrix metalloproteinase 9/sang , Matrix metalloproteinase 9/génétique , microARN/sang , microARN/génétique , Facteur de croissance endothéliale vasculaire de type A/sang , Facteur de croissance endothéliale vasculaire de type A/génétique , Facteur de croissance endothéliale vasculaire de type A/métabolismeRÉSUMÉ
OBJECTIVE: The study aimed to alert the neonatal community to the possibility of multisystem inflammatory syndrome in children (MIS-C) like disease in critically ill neonates born to mothers with coronavirus disease 2019 (COVID-19). STUDY DESIGN: Diagnosis of MIS-C like disease was pursued after echocardiography showed severely depressed ventricular function and pathological coronary artery dilation in the setting of medically refractory multisystem organ failure and maternal COVID-19 infection. The neonate did not respond to standard medical therapy, and there was no alternative disease that could explain the clinical course. High index of clinical suspicion coupled with low risk of intravenous immunoglobulin (IVIG) prompted us to pursue IVIG administration even though the neonate did not meet classic criteria for MIS-C. RESULT: Following treatment with IVIG, there was rapid clinical improvement. Ventricular function improved within 15 hours and coronary artery dilation resolved in 8 days. There was no recurrence of disease during follow-up. CONCLUSION: COVID-19 associated MIS-C like disease has not been well described in neonates. As typical features may be conspicuously absent, a high index of suspicion is warranted in critically ill neonates born to mothers with COVID-19. Echocardiography may provide critical diagnostic information and narrow the differential diagnosis. KEY POINTS: · COVID-19 associated MIS-C can present in neonates.. · Echocardiography is helpful in raising suspicion for MIS-C in neonates.. · Consider MIS-C in the differential diagnosis of ill neonates born to mothers with COVID-19..
Sujet(s)
COVID-19 , Maladie grave/thérapie , Échocardiographie/méthodes , Immunoglobulines par voie veineuse/administration et posologie , Maladies néonatales , Complications infectieuses de la grossesse , Syndrome de réponse inflammatoire généralisée , COVID-19/complications , COVID-19/diagnostic , COVID-19/épidémiologie , COVID-19/physiopathologie , COVID-19/thérapie , COVID-19/virologie , Vaisseaux coronaires/imagerie diagnostique , Vaisseaux coronaires/effets des médicaments et des substances chimiques , Diagnostic différentiel , Femelle , Humains , Facteurs immunologiques/administration et posologie , Nouveau-né , Maladies néonatales/diagnostic , Maladies néonatales/physiopathologie , Maladies néonatales/thérapie , Maladies néonatales/virologie , Grossesse , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , SARS-CoV-2/isolement et purification , Syndrome de réponse inflammatoire généralisée/diagnostic , Syndrome de réponse inflammatoire généralisée/physiopathologie , Syndrome de réponse inflammatoire généralisée/thérapie , Syndrome de réponse inflammatoire généralisée/virologie , Résultat thérapeutique , Fonction ventriculaire/effets des médicaments et des substances chimiquesRÉSUMÉ
OBJECTIVE. Subpial hemorrhages, typically seen in neonates, are rare but can harm the adjacent brain parenchyma. The purpose of this review is to summarize the anatomy and pathophysiology of subpial hemorrhage and highlight its characteristic neuro-imaging pattern. CONCLUSION. The distinctive neuroimaging pattern of subpial hemorrhage is best appreciated on brain MRI, which shows the morphology over the cortex and injury to adjacent cortex and subcortical white matter. These findings do not occur in subarachnoid and subdural hemorrhages. Recognizing the pattern of subpial hemorrhages should guide prognostic precision, prognostication, and counseling.
Sujet(s)
Maladies néonatales/imagerie diagnostique , Hémorragie meningée/imagerie diagnostique , Encéphale/imagerie diagnostique , Humains , Nourrisson , Nouveau-né , Maladies néonatales/physiopathologie , Imagerie par résonance magnétique , Neuroimagerie , Pie-mère/imagerie diagnostique , Facteurs de risque , Hémorragie meningée/physiopathologie , TomodensitométrieRÉSUMÉ
BACKGROUND: Cooling delays, temperature outside 33-34 °C, and blood pressure below the mean arterial blood pressure with optimal cerebral autoregulation (MAPOPT) might diminish neuroprotection from therapeutic hypothermia in neonates with hypoxic-ischemic encephalopathy (HIE). We hypothesized that longer time to reach temperature <34 °C and having temperature outside 33-34 °C would be associated with worse autoregulation and greater brain injury. METHODS: Neonates with HIE had rectal temperature and near-infrared spectroscopy autoregulation monitoring during hypothermia (n = 63) and rewarming (n = 58). All underwent brain MRI, and a subset received diffusion tensor imaging MRI before day 10 (n = 41). RESULTS: Most neonates reached <34 °C at 3-6 h of life. MAPOPT was identified in 54/63 (86%) during hypothermia and in 53/58 (91%) during rewarming. Cooling time was not related to blood pressure deviation from MAPOPT. Later cooling was associated with lower ADC scalar in unilateral posterior centrum semiovale but not in other regions. Temperatures >34 °C were associated with blood pressure above MAPOPT but not with brain injury. CONCLUSIONS: In neonates who were predominantly cooled after 3 h, cooling time was not associated with autoregulation or overall brain injury. Blood pressure deviation above MAPOPT was associated with temperature >34 °C. Additional studies are needed in a more heterogeneous population. IMPACT: Cooling time to reach target hypothermia temperature within 6 h of birth did not affect cerebral autoregulation measured by NIRS in neonates with hypoxic-ischemic encephalopathy (HIE). Temperature fluctuations >33-34 °C were associated with blood pressures that exceeded the range of optimal autoregulatory vasoreactivity. Cooling time within 6 h of birth and temperatures >33-34 °C were not associated with qualitative brain injury on MRI. Regional apparent diffusion coefficient scalars on diffusion tensor imaging MRI were not appreciably affected by cooling time or temperature >33-34 °C. Additional research in a larger and more heterogeneous population is needed to determine how delayed cooling and temperatures beyond the target hypothermia range affect autoregulation and brain injury.
Sujet(s)
Hypothermie provoquée , Hypoxie-ischémie du cerveau/thérapie , Maladies néonatales/thérapie , Pression artérielle , Circulation cérébrovasculaire , Imagerie par résonance magnétique de diffusion , Femelle , Homéostasie , Humains , Hypothermie provoquée/effets indésirables , Hypoxie-ischémie du cerveau/diagnostic , Hypoxie-ischémie du cerveau/physiopathologie , Nouveau-né , Maladies néonatales/diagnostic , Maladies néonatales/physiopathologie , Unités de soins intensifs néonatals , Mâle , Projets pilotes , Études prospectives , Spectroscopie proche infrarouge , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
The next phase of clinical trials in neonatal encephalopathy (NE) focuses on hypothermia adjuvant therapies targeting alternative recovery mechanisms during the process of hypoxic brain injury. Identifying infants eligible for neuroprotective therapies begins with the clinical detection of brain injury and classification of severity. Combining a variety of biomarkers (serum, clinical exam, EEG, movement patterns) with innovative clinical trial design and analyses will help target infants with the most appropriate and timely treatments. The timing of magnetic resonance imaging (MRI) and MR spectroscopy after NE both assists in identifying the acute perinatal nature of the injury (days 3-7) and evaluates the full extent and evolution of the injury (days 10-21). Early, intermediate outcome of neuroprotective interventions may be best defined by the 21-day neuroimaging, with recognition that the full neurodevelopmental trajectory is not yet defined. An initial evaluation of each new therapy at this time point may allow higher-throughput selection of promising therapies for more extensive investigation. Functional recovery can be assessed using a trajectory of neurodevelopmental evaluations targeted to a prespecified and mechanistically derived hypothesis of drug action. As precision medicine revolutionizes healthcare, it should also include the redesign of NE clinical trials to allow safe, efficient, and targeted therapeutics. IMPACT: As precision medicine revolutionizes healthcare, it should also include the redesign of NE clinical trials to allow faster development of safe, effective, and targeted therapeutics. This article provides a multidisciplinary perspective on the future of clinical trials in NE; novel trial design; study management and oversight; biostatistical methods; and a combination of serum, imaging, and neurodevelopmental biomarkers can advance the field and improve outcomes for infants affected by NE. Innovative clinical trial designs, new intermediate trial end points, and a trajectory of neurodevelopmental evaluations targeted to a prespecified and mechanistically derived hypothesis of drug action can help address common challenges in NE clinical trials and allow for faster selection and validation of promising therapies for more extensive investigation.
Sujet(s)
Recherche biomédicale/tendances , Encéphalopathies/thérapie , Essais cliniques comme sujet , Maladies néonatales/thérapie , Néonatologie/tendances , Plan de recherche/tendances , Marqueurs biologiques/sang , Encéphalopathies/imagerie diagnostique , Encéphalopathies/étiologie , Encéphalopathies/physiopathologie , Consensus , Méthode Delphi , Diffusion des innovations , Prévision , Humains , Nouveau-né , Maladies néonatales/imagerie diagnostique , Maladies néonatales/étiologie , Maladies néonatales/physiopathologie , Neuroimagerie , Sociétés médicales , Sociétés savantes , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
Extracellular vesicles (EVs) are cell-derived membrane-bound particles, extensively investigated across many fields to improve the understanding of pathophysiological processes, as biomarkers of disease and as therapeutic targets for pharmacological intervention. We aim to describe the current knowledge of EVs detected in the body fluids of human neonates, both term and preterm, from birth to 4 weeks of age. To date, EVs have been described in several neonatal body fluids, including cerebrospinal fluid, umbilical cord blood, neonatal blood, tracheal aspirates and urine. These studies demonstrate some important roles of EVs in the neonatal population, particularly in haemostasis. Moreover, some studies have demonstrated the pathophysiological mechanisms and the identification of potential biomarkers of neonatal disease. We must continue to build on this knowledge, evaluating the role of EVs in neonatal pathology, particularly in prematurity and during the perinatal adaption period. Future studies should use larger numbers, robust EV characterisation techniques and always correlate the findings to clinical outcomes. IMPACT: This article summarises the current knowledge of the effect of EVs in neonates. It describes the potential compensatory role of EVs in neonatal haemostasis. It also describes the role of EVs as mediators of pathology and as potential biomarkers of perinatal and neonatal disease.
Sujet(s)
Vésicules extracellulaires/anatomopathologie , Maladies néonatales/anatomopathologie , Marqueurs biologiques/métabolisme , Développement de l'enfant , Vésicules extracellulaires/métabolisme , Hémostase , Humains , Nouveau-né , Maladies néonatales/sang , Maladies néonatales/physiopathologieRÉSUMÉ
OBJECTIVE: To analyze auditory brainstem response (ABR) findings of preterm and term infants in the neonatal intensive care unit (NICU) with perinatal problems. STUDY DESIGN: Case series with chart review. SETTING: Secondary care hospital. METHODS: Analysis consisted of a consecutive series of 101 infants (69 preterm and 32 term) admitted in the NICU of Hospital Fernando Fonseca between 2016 and 2018 with perinatal problems who underwent an ABR evaluation. RESULTS: The major perinatal problems identified were hyperbilirubinemia, intravenous gentamicin >5 days, mechanical ventilation >5 days, congenital cytomegalovirus infection, meningitis, and periventricular hemorrhage. Gentamicin use significantly increased the absolute latency of wave I in preterm infants (95% CI, 0.01-0.37; P = .037). Mechanical ventilation significantly decreased the latency of wave V and intervals I-V and III-V in preterm infants (95% CI, -0.35 to -0.22; P = .026; 95% CI, -0.33 to -0.00; P = .001; 95% CI, -0.46 to 0.12; P = .049). Congenital cytomegalovirus significantly decreased interval III-V in preterm infants (95% CI, -0.36 to -0.01; P = .042).Multivariate analysis revealed that gentamicin use, lower gestational age, and lower birth weight predicted an increased ABR threshold in preterm infants (95% CI, 1.64-15.31; P = .016; 95% CI -1.72 to -0.09; P = .030; 95% CI, -14.55 to -0.63; P = .033). ABR measurements in term infants were not significantly altered, with the exception of an increased latency of wave III with a lower gestational age (95% CI, -0.49 to -0.01; P = .038). CONCLUSIONS: These findings suggest that perinatal problems in the NICU significantly impair the ABR threshold and the auditory pathway maturational process in preterm but not term infants.
Sujet(s)
Potentiels évoqués auditifs du tronc cérébral , Maladies néonatales/physiopathologie , Femelle , Humains , Nouveau-né , Prématuré , Unités de soins intensifs néonatals , MâleRÉSUMÉ
Appropriate treatment of neonatal seizures with an effective therapy is important in reducing long-term neurologic disabilities. Sixty-seven neonates, who received intravenous (IV) levetiracetam (LEV) as first-line therapy for treating seizures between 2013 and 2017 were evaluated retrospectively to investigate the efficacy of LEV and its neurodevelopmental outcome at 12 months of age. Of the 67 neonates (44 preterm and 23 term babies) evaluated for seizures, 55 (82%) had a defined etiology. EEG confirmation was obtained in 36 (57.1%) of the neonates with clinical seizures. On the 7th day of the treatment (mean seizure control time 7.4 ± 15.1 days), LEV was effective as monotherapy in 43 (64%), whereas add-on therapy was required in 24 (36%) neonates. At the 1-year follow-up, 76% of infants achieved drug-free state, nine (18%) infants remained on LEV monotherapy and three (6%) needed add-on therapy. Neurodevelopmental outcome of the infants was assessed with Ankara Development Screening Inventory and results suggested favorable neurodevelopmental outcome in 69.7% of the infants with at the end of the 1-year follow-up with LEV monotherapy. In conclusion, this retrospective cross-sectional study demonstrated that IV LEV is an effective first-line therapy for treating neonatal clinical seizures and LEV monotherapy effect was sustained during the first year follow-up.
Sujet(s)
Anticonvulsivants/usage thérapeutique , Développement de l'enfant/effets des médicaments et des substances chimiques , Prématuré/croissance et développement , Lévétiracétam/usage thérapeutique , Crises épileptiques/traitement médicamenteux , Anticonvulsivants/pharmacologie , Développement de l'enfant/physiologie , Études transversales , Électroencéphalographie/méthodes , Études de suivi , Humains , Nourrisson , Nouveau-né , Maladies néonatales/traitement médicamenteux , Maladies néonatales/physiopathologie , Lévétiracétam/pharmacologie , Études rétrospectives , Crises épileptiques/physiopathologie , Résultat thérapeutiqueRÉSUMÉ
PURPOSE: To describe neonatal-onset congenital ectropion uveae (N-CEU) as a distinct clinical entity of newborn glaucoma (NG) and to study its significance toward the severity and outcome of NG. DESIGN: Prospective clinical cohort study. METHODS: The study took place at a tertiary care postgraduate teaching institute. It included consecutive patients with NG who presented between July 1, 2016 and September 30, 2017, with a minimum postoperative follow-up of 1 year. Infants with any ocular anomaly apart from CEU were excluded. Patients with N-CEU were compared with those with neonatal-onset primary congenital glaucoma (N-PCG). All infants underwent goniotomy or trabeculotomy, with trabeculectomy depending on corneal clarity. Clinical features at presentation and outcome 1 year after surgery were defined as good or satisfactory if intraocular pressure was ≤16.0 mm Hg under anesthesia without or with topical medications, respectively, and poor if the infant required additional surgery. RESULTS: Twenty eyes of 10 patients with N-CEU were compared with 16 eyes of 9 patients with N-PCG. Infants with N-CEU had significantly worse corneal clarity (mean grade 2.0 ± 0.7 vs 1.4 ± 0.8; P = .026) and poorer outcomes compared with those with N-PCG. Seven of 16 (43.7%) eyes with N-PCG had a cornea clear enough at presentation for a goniotomy compared with only 2 of the 20 (10%) eyes with N-CEU (P = .026). Thirteen of 16 (81.2%) eyes with N-PCG had a good or satisfactory outcome compared with 6 of 20 (30%) eyes with N-CEU (P = .001). CONCLUSIONS: N-CEU appears to be distinct from the unilateral CEU in older patients described in the literature and may be considered a poorer prognosis phenotype of neonatal-onset glaucoma.
Sujet(s)
Ectropion/congénital , Hydrophtalmie/diagnostic , Maladies néonatales/diagnostic , Ectropion/épidémiologie , Ectropion/physiopathologie , Femelle , Études de suivi , Gonioscopie , Humains , Hydrophtalmie/épidémiologie , Hydrophtalmie/physiopathologie , Incidence , Nourrisson , Nouveau-né , Maladies néonatales/épidémiologie , Maladies néonatales/physiopathologie , Pression intraoculaire/physiologie , Mâle , Phénotype , Études prospectives , Tonométrie oculaire , TrabéculectomieRÉSUMÉ
OBJECTIVE: To summarise currently reported neonatal cases of SARS-CoV-2 infection. METHODS: A search strategy was designed to retrieve all articles published from 1 December 2019 to 12 May 2020, by combining the terms 'coronavirus' OR 'covid' OR 'SARS-CoV-2') AND ('neonat*' OR 'newborn') in the following electronic databases: MEDLINE/Pubmed, Scopus, Web of Science, MedRxiv, the Cochrane Database of Systematic Review and the WHO COVID-19 database, with no language restrictions. Quality of studies was evaluated by using a specific tool for assessment of case reports and/or case series. RESULTS: Twenty-six observational studies (18 case reports and 8 case series) with 44 newborns with confirmed SARS-CoV-2 infection were included in the final analysis. Studies were mainly from China and Italy. Half of neonates had a documented contact with the infected mother and one out of three infected neonates was admitted from home. Median age at diagnosis was 5 days. One out of four neonates was asymptomatic, and the remaining showed mild symptoms typical of acute respiratory infections and/or gastrointestinal symptoms. The majority of neonates were left in spontaneous breathing (room air) and had good prognosis after a median duration of hospitalisation of 10 days. CONCLUSIONS: Most neonates with SARS-CoV-2 infection were asymptomatic or presented mild symptoms, generally were left in spontaneous breathing and had a good prognosis after median 10 days of hospitalisation. Large epidemiological and clinical cohort studies, as well as the implementation of collaborative networks, are needed to improve the understanding of the impact of SARS-CoV-2 infection in neonates.
Sujet(s)
COVID-19 , Maladies néonatales , Complications infectieuses de la grossesse , COVID-19/diagnostic , COVID-19/épidémiologie , COVID-19/physiopathologie , COVID-19/thérapie , Femelle , Santé mondiale , Humains , Nouveau-né , Maladies néonatales/diagnostic , Maladies néonatales/épidémiologie , Maladies néonatales/physiopathologie , Maladies néonatales/thérapie , Transmission verticale de maladie infectieuse/statistiques et données numériques , Gestion des soins aux patients , Grossesse , Complications infectieuses de la grossesse/épidémiologie , Complications infectieuses de la grossesse/virologie , Pronostic , SARS-CoV-2RÉSUMÉ
Clinical signs and neuroimaging patterns associated with the fetal inflammatory response syndrome (FIRS) worsen or mimic the clinical repertoire after intrapartum hypoxic-ischemic encephalopathy (HIE) during labor and/or parturition. Diagnostic considerations expressed as neonatal encephalopathy (NE) must consider chronic as well as acute factors associated with FIRS. Trimester-specific factors adversely alter the interactions of the maternal/placental/fetal (MPF) triad and influence the postnatal phenotype of FIRS. Anticipatory guidance for families by clinicians caring for survivors with FIRS, as well as researchers, must consider acute and chronic effects that influence neurologic outcome. Novel neurotherapeutic interventions must include prenatal preventive as well as peripartum/postnatal rescue and repair strategies to effectively reduce the presence and severity of sequelae from FIRS.
Sujet(s)
Chorioamnionite/physiopathologie , Hypoxie-ischémie du cerveau/physiopathologie , Adulte , Chorioamnionite/diagnostic , Femelle , Humains , Hypoxie-ischémie du cerveau/étiologie , Nouveau-né , Maladies néonatales/physiopathologie , Grossesse , Issue de la grossesseRÉSUMÉ
INTRODUCTION: A novel coronavirus named severe acute respiratory syndrome coronavirus 2, was first reported in Wuhan, China, in December 2019. The virus, known as COVID-19, is recognized as a potentially life-threatening disease by causing severe respiratory disease. Since this virus has not previously been detected in humans, there is a paucity of information regarding its effects on humans. In addition, only limited or no information exists about its impact during pregnancy. CASE PRESENTATION: In the present case study, we report the death of a neonate born to a 32-year-old mother with coronavirus disease 2019 in Ilam, Iran, with Kurdish ethnicity. We report the infection and death of a neonate in Iran with a chest X-ray (CXR) marked abnormality 2 hours after birth demonstrating coronavirus disease 2019 disease. The neonate was born by elective cesarean section, the fetal health was assessed using fetal heart rate and a non-stress test before the birth, and there was no evidence of fetal distress. All the above-mentioned facts and radiographic abnormalities suggested that coronavirus disease 2019 is involved. CONCLUSIONS: In this case study, we report the death of a neonate born to a mother with coronavirus disease 2019, 11 hours after birth. There is a paucity of data on the vertical transmission and the adverse maternal-fetal consequences of this disease, so vertical transmission from mother to child remains to be confirmed.
Sujet(s)
Betacoronavirus/isolement et purification , Infections à coronavirus , Soins de réanimation/méthodes , Maladies néonatales , Pandémies , Pneumopathie virale , Complications infectieuses de la grossesse , Adulte , COVID-19 , Césarienne/méthodes , Aggravation clinique , Infections à coronavirus/diagnostic , Infections à coronavirus/physiopathologie , Infections à coronavirus/thérapie , Infections à coronavirus/transmission , Issue fatale , Femelle , Humains , Nouveau-né , Maladies néonatales/diagnostic , Maladies néonatales/physiopathologie , Maladies néonatales/thérapie , Transmission verticale de maladie infectieuse , Iran , Dépistage néonatal/méthodes , Mort périnatale , Pneumopathie virale/diagnostic , Pneumopathie virale/physiopathologie , Pneumopathie virale/thérapie , Pneumopathie virale/transmission , Grossesse , Complications infectieuses de la grossesse/diagnostic , Complications infectieuses de la grossesse/physiopathologie , Complications infectieuses de la grossesse/thérapie , Ventilation artificielle/méthodes , SARS-CoV-2RÉSUMÉ
BACKGROUND: To evaluate the utility of echocardiogram (ECHO) in detection and treatment of patent ductus arteriosus (PDA) and hemodynamically significant PDA (hsPDA) in preterm neonates. METHODS: This was a retrospective case-control study of all preterm infants born or admitted to the level III Neonatal Intensive Care Unit in McMaster Children's Hospital from January 2009 to January 2013. These cases were further classified into the following sub-groups: group A) hsPDA confirmed on ECHO; and the control, group B) PDA (but not hemodynamically significant) confirmed on ECHO. Patients without an ECHO were excluded from all analyses. The primary outcome was incidence of treatment for PDA. RESULTS: PDA treatment was administered in 83.3% and 11.2% of patients in groups A and B respectively (Pâ<â0.05). Among patients with a hsPDA within group A, 17% did not receive treatment, while 11% of patients with non-hemodynamically significant PDA received treatment for the PDA. Within the cohort of patients who received treatment for a hsPDA, gestational age below 35 weeks as well as murmurs heard on auscultation were both found to be predictors of treatment. CONCLUSION: While the ECHO remains the gold standard for detecting pathological PDA, there is evidence that other traditional clinical measures continue to guide clinical practice and treatment decisions. Further research is required to gain an understanding of how clinical measures and ECHO may be used in conjunction to optimize resource utilization.